Detalles de la búsqueda
1.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Hematol Oncol
; 40(5): 1009-1019, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35638723
2.
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients.
Eur J Haematol
; 108(3): 178-189, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716957
3.
Carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 100(2): 429-436, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33161453
4.
Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
Ann Hematol
; 98(6): 1449-1455, 2019 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-30868307
5.
Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Ann Hematol
; 97(10): 1817-1824, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30054707
6.
Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen.
Br J Haematol
; 172(1): 111-21, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26458240
7.
Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials.
Front Oncol
; 12: 890376, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35924160
8.
Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Ann Hematol
; 90(12): 1449-56, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21437586
9.
Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Br J Haematol
; 144(5): 653-9, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19036082
10.
Outcomes of Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Hodgkin Lymphomas: A Retrospective Multicenter Experience by the Rete Ematologica Pugliese (REP).
Clin Lymphoma Myeloma Leuk
; 19(1): 35-40, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30293754
11.
Serum C-reactive protein at diagnosis and response to therapy is the most powerful factor predicting outcome of multiple myeloma treated with thalidomide/ anthracycline-based therapy.
Clin Lymphoma Myeloma
; 8(5): 294-9, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18854284
12.
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Leuk Lymphoma
; 64(10): 1715-1718, 2023 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-37417467
13.
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab.
Leuk Lymphoma
; 47(12): 2542-6, 2006 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-17169798
14.
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma.
Hematol J
; 5(4): 312-7, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15297847
15.
High-dose daunorubicin as liposomal compound (Daunoxome) in elderly patients with acute lymphoblastic leukemia.
Hematol J
; 4(1): 47-53, 2003.
Artículo
en Inglés
| MEDLINE | ID: mdl-12692520
16.
Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the 'Rete Ematologica Pugliese E Basilicata'.
Leuk Lymphoma
; 60(14): 3565-3568, 2019 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-31286780
17.
Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide.
Leuk Lymphoma
; 52(5): 776-85, 2011 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-21338282
18.
Melphalan, prednisone, and thalidomide versus thalidomide, dexamethasone, and pegylated liposomal doxorubicin regimen in very elderly patients with multiple myeloma: a case-match study.
Leuk Lymphoma
; 51(8): 1444-9, 2010 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-20496998
19.
Gemtuzumab ozogamicin plus cytarabine determines complete remission in acute myeloid leukemia refractory to a double conventional treatment: a case report.
Haematologica
; 89(6 Suppl): ECR18, 2004 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-15194554
20.
Technetium-99m sestamibi scintigraphy is sensitive and specific for the staging and the follow-up of patients with multiple myeloma: a multicentre study on 397 scans.
Br J Haematol
; 136(5): 729-35, 2007 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-17233770